Strategies for the determination of pharmacophoric 3D database queries

Journal of Computer-Aided Molecular Design

Volumn 11, Issue 1, 1997, Pages 39-52

  Van Drie, John H ^a  

^a PFIZER INC   (United States)

Author keywords

3D database; ACE pharmacophore; D2 antagonist pharmacophore; Database query; Pharmacophore; RGD pharmacophore; Selectivity principle; 2 antagonist pharmacophore

Indexed keywords

PHARMACODYNAMICS; QUERY LANGUAGES;

3D DATABASE; ANGIOTENSIN-CONVERTING ENZYME; ANGIOTENSIN-CONVERTING ENZYME PHARMACOPHORE; D2-ANTAGONIST PHARMACOPHORE; DATABASE QUERIES; PHARMACOPHORES; RGD PHARMACOPHORE; SELECTIVITY PRINCIPLE; Β2-ANTAGONIST PHARMACOPHORE;

QUERY PROCESSING;

ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; FIBRINOGEN; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG DESIGN; FACTUAL DATABASE; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-ANTAGONISTS; AMINO ACID SEQUENCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DATABASES, FACTUAL; DOPAMINE ANTAGONISTS; DRUG DESIGN; FIBRINOGEN; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030639430     PISSN: 0920654X     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1008019326401     Document Type: Article

References (27)

1. a. Kuntz, I.D., Blaney, J.M., Oatley, S.J., Langridge, R. and Ferrin, T.E., J. Mol. Biol., 161 (1982) 269.
2. b. DesJarlais, R.L., Sheridan, R.P., Dixon, J.S., Kuntz, I.D. and Venkataraghavan, R., J. Med. Chem., 29 (1986) 2149.
3. Gund, P., Annu. Rep. Med. Chem., 14 (1979) 299.
4. Brint, A.T. and Willett, P., J. Mol. Graph., 5 (1987) 49.
5. VanDrie, J.H., Weininger, D. and Martin, Y.C., J. Comput.-Aided Mol. Design, 3 (1989) 255.
6. Sheridan, R.P., Nilakantan, R., Rusinko, A., Bauman, N., Haraki, K.S. and Venkataraghavan, R., J. Chem. Inf. Comput. Sci., 29 (1989) 255.
7. a. Christie, B.D., Henry, D.R., Güner, O.F. and Moock, T.E., Online Inf., 90 (1990) 137.
8. b. Moock, T.E., Henry, D.R., Ozkabak, A.G. and Alamgir, M., J. Chem. Inf. Comput. Sci., 34 (1994) 184.
9. Murrall, N.W. and Davies, E.K., J. Chem. Inf. Comput. Sci., 30 (1990) 312.
10. Van Drie, J.H., Berezin, S. and Ku, S.-L., Abstracts for the ACS National Meeting, Spring, 1992, CINF 023. No detailed description of the Catalyst 3D database searching software has been published.
11. Hurst, T., J. Chem. Inf. Comput. Sci., 34 (1994) 190. No further details have been published on the Unity 3D database searching software.
12. Marshall, G.R. and Cramer, R.D., Trends Pharmacol. Sci., 9 (1988) 285.
13. Good, A.C. and Mason, J.S., In Lipkowitz, K.B. and Boyd, D.B. (Eds.) Reviews in Computational Chemistry, Vol. 7, VCH, New York, NY, U.S.A., 1996, pp. 67-117.
14. Mayer, D., Naylor, C.B., Motoc, I. and Marshall, G.R., J. Comput.-Aided Mol. Design, 1 (1987) 3.
15. Ondetti, M.A., Cushman, D.W. and Rubin, B., In Bindra, J.S. and Lednicer, D. (Eds.) Chronicles of Drug Discovery, Vol. 2, Wiley, New York, NY, U.S.A., 1983, pp. 1-31.
16. Seeman, P., Watanabe, M., Grigoriadis, D., Tedesco, J.L., George, S.R., Svensson, U., Nilsson, J.L. and Neumeyer, J.L., Mol. Pharmacol., 28 (1985) 391.
17. a. Bartlett, P.A., Shea, G.T., Telfer, S.J. and Waterman, S., In Roberts, S.M. (Ed.) Molecular Recognition: Chemical and Biological Problems, Vol. 78, Royal Society of Chemistry, London, U.K., 1989, pp. 182-192.
18. b. Lauri, G. and Bartlett, P.A., J. Comput.-Aided Mol. Design, 8 (1994) 51.
19. Van Drie, J.H. and Martin, Y.C., Workshop on 3D databases at the Crystallography and Drug Design Conference, Erice, Italy, June 1989.
20. Karlin, S. and Brendel, V., Science, 257 (1992) 39.
21. Van Drie, J.H., J. Comput.-Aided Mol. Design, 10 (1996) 623.
22. Lloyd, E.J. and Andrews, P.J., J. Med. Chem., 29 (1986) 453. Note that, while we identify the basic amine as a 'positive-charge' group, they identify it as an H-bond donor. It is difficult to say precisely what the protonation state of that nitrogen is when bound to the receptor.
23. Strader, C.D., Sigal, I.S. and Dixon, R.A.F., FASEB J., 3 (1989) 1825.
24. Mansch, C., Sammes, P.G. and Taylor, P.G. (Eds.) Comprehensive Medicinal Chemistry, Pergamon, Oxford, U.K., 1990.
25. Samanen, J., Ali, F., Romoff, T., Calvo, R., Sorenson, E., Vasko, J., Storer, B., Berry, D., Bennett, D., Strohsacker, M., Powers, D., Stadel, J. and Nichols, A., J. Med. Chem., 34 (1991) 3114.
26. Hartman, G.D., Egbertson, M.S., Halczenko, W., Laswell, W.L., Duggan, M.E., Smith, R.L., Naylor, A.M., Manno, P.D., Lynch, R.J., Zhang, G., Chang, C.T.-C. and Gould, R.J., J. Med. Chem., 35 (1992) 4640.
27. The Catalyst software is available from Molecular Simulations Inc., San Diego, CA, U.S.A. Conformers were generated using the so-called 'fast' methodology (torsion-angle driving with energy-minimization post-processing) with an 8.0 kcal/mol cutoff. Up to 150 conformers/molecule were generated. The flexible database searching used does not perform any on-the-fly manipulation of the conformers, but rather relies strictly on the conformers stored in the database. There is some difference between the way in which Catalyst defines features and the way in which the custom software implementing the procedure of Mayer et al. defines them, especially for the 'hydrophobic' feature. However, in principle, one should be able to reproduce this analysis with any method of conformational analysis which effectively explores all energetically reasonable regions of conformational space, and any database search system which allows one both to express the concepts we discuss here, and which takes into account conformational flexibility in analyzing a molecule for possible hits.